What is European patent EP 0 489 837 for Tysabri (natalizumab)?
EP 0 489 837 is an International Publication/EP record number associated with intellectual property around natalizumab-based therapies (Tysabri is natalizumab). Patent records with this kind of identifier can cover things such as the antibody molecule, its composition or formulation, and related methods of treatment, depending on what each claim set covers.
However, the exact scope of EP 0 489 837 (what the claims cover, the assignee, priority dates, and how it maps to natalizumab/Tysabri) requires checking the official European Patent Register entry for that specific EP publication number.
How do I verify the exact EP 0 489 837 entry (publication vs patent number)?
European filings can appear under different identifiers, and users often mix them up. When you see “EP 0 489 837,” it may refer to:
- an EP publication number (what you see publicly during publication),
- a granted EP patent number later, or
- a family member’s publication number.
To confirm you have the right document, check at least:
- publication number format exactly as shown (including dots/spaces),
- applicant/assignee name,
- publication date,
- priority date(s).
When does the patent or exclusivity expire?
Expiration depends on:
- the priority date,
- whether the patent was granted,
- any patent term adjustments/extensions (where applicable in Europe),
- and whether additional protections exist (for example, Supplementary Protection Certificates, if the underlying product qualifies).
Without the specific EP entry details (priority date and status), the expiration date can’t be stated accurately.
Where can I look up EP 0 489 837?
You can verify and pull the precise legal status and bibliographic data from:
- Espacenet (European Patent Office) for the EP publication/patent record,
- the European Patent Register/legal status tools for grant/status information.
If you paste the assignee/applicant name shown on your EP 0 489 837 record or share the link you’re looking at, I can help interpret what the claims likely cover (e.g., composition vs method) and how it relates to Tysabri’s molecule and use.
Can biosimilars or follow-on antibodies launch in Europe before this patent expires?
Even if a particular EP patent (like EP 0 489 837) expires or is narrow, other patents in the same family or separate patent families can block entry. In practice, biosimilar/follow-on development also needs to navigate:
- patent landscapes beyond a single number,
- possible SPC protection,
- and enforcement/litigation status.
A precise answer needs the patent’s scope and legal status.
If you share the document link, what can I extract for you?
With the EP 0 489 837 Espacenet link or the bibliographic details (title, assignee, priority date, publication date), I can summarize:
- the invention/purpose from the abstract,
- what the independent claims appear to cover,
- whether it looks directly tied to natalizumab itself vs a method of use,
- and the most likely remaining timeline based on status.
Quick clarifying question
Can you paste the Espacenet link or the exact title/assignee shown on “European patent 0 489 837”?